Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib.
Celecoxib is a hydrophobic and highly permeable drug belonging to class II of biopharmaceutics classification system. Low aqueous solubility of celecoxib leads to high variability in absorption after oral administration. Cohesiveness, low bulk density and compressibility, and poor flow properties of celecoxib impart complications in it's processing into solid dosage forms. To improve the solubility and bioavailability and to get faster onset of action of celecoxib, the self-microemulsifying drug delivery system (SMEDDS) was developed. Composition of SMEDDS was optimized using simplex lattice mixture design. Dissolution efficiency, t(85%), absorbance of diluted SMEDDS formulation and solubility of celecoxib in diluted formulation were chosen as response variables. The SMEDDS formulation optimized via mixture design consisted of 49.5% PEG-8 caprylic/capric glycerides, 40.5% mixture of Tween20 and Propylene glycol monocaprylic ester (3:1) and 10% celecoxib, which showed significantly higher rate and extent of absorption than conventional capsule. The relative bioavailability of the SMEDDS formulation to the conventional capsule was 132%. The present study demonstrated the suitability of mixture design to optimize the compositions for SMEDDS. The developed SMEDDS formulations have the potential to minimize the variability in absorption and to provide rapid onset of action of celecoxib.
Subramanian
Natesan
N
Division of Pharmaceutics, Department of Pharmaceutical Technology, Jadavpur University, India.
Ray
Subhabrata
S
Ghosal
Saroj Kumar
SK
Bhadra
Ranjan
R
Moulik
Satya Priya
SP
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D000068579:Celecoxib; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems / Q000379:methods*; D045703:Emulsifying Agents / Q000008:administration & dosage* / Q000097:blood*; D006801:Humans; D008297:Male; D011720:Pyrazoles / Q000008:administration & dosage* / Q000097:blood*; D012995:Solubility; D013449:Sulfonamides / Q000008:administration & dosage* / Q000097:blood*
D045703:Emulsifying Agents; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib